Peptides
Evidence: strong_human
Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.
Standard: Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
Maintenance: Research indicates 100-200 mcg at bedtime for maintenance.
Administration: subcutaneous
Timing: Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
Duration: 12-24 week cycles. Some protocols use continuous treatment.
Sermorelin was FDA-approved in 1997 for pediatric GH deficiency diagnosis and treatment, giving it one of the strongest safety profiles in the GHRH category. Discontinued in 2008 due to manufacturing issues (not safety). Short half-life (11-12 minutes) means it produces physiological GH pulses. Commonly considered the safest entry point for GH optimization. Stacking with a GHRP (Ipamorelin preferred) provides synergistic amplification of GH release.
Compounding pharmacy (503A/503B). Was previously FDA-approved (1997) but discontinued in 2008 due to manufacturing difficulties, not safety concerns.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →